Singapore National Eye Centre, Singapore, Republic of Singapore.
J Glaucoma. 2013 Mar;22(3):190-4. doi: 10.1097/IJG.0b013e318237c6c4.
Nonadherence to glaucoma medications may be a major cause of treatment failure. We examined the acceptance of glaucoma patients toward a possible new route of administering glaucoma medication by subconjunctival injection.
Patients were recruited from specialist glaucoma clinics on a voluntary basis. Trained interviewers administered a 30-item questionnaire and an information sheet with details of an alternative subconjunctival injection route involving injections at 3-month intervals. Outcome measures regarding acceptance of the new procedure, social situational factors, disease factors, and treatment factors were assessed.
A total of 151 patients participated in this study. Of the 151 patients 112 (74.2%) were willing to have their glaucoma medication given by the new method of subconjunctival injection, 101 of 112 (90.2%) were willing to accept it at the same cost as their present medication, and 87 of 101 (86.1%) were willing to accept it even at a higher cost. These patients tended to be on a greater number of medications (P=0.006), and medicating more frequently in a day (P=0.003). Nine of 10 (90%) patients who were admitted to nonadherence were willing to accept subconjunctival injections at 3-month intervals in place of their topical medication.
Our study found that 74% of glaucoma patients were willing to accept an alternative form of glaucoma treatment through 3-monthly subconjunctival injections. A large proportion of patients who were admitted to nonadherence to topical medication were willing to consider this alternative method of medication. Our findings are helpful when developing patient-acceptable drug-delivery regimes, which may alleviate the need for daily medication.
不遵医嘱使用青光眼药物可能是治疗失败的主要原因。我们研究了患者对可能通过结膜下注射给予青光眼药物的新途径的接受程度。
患者自愿从专科青光眼诊所招募。经过培训的访谈员采用 30 项问卷和一份信息表对患者进行评估,信息表详细说明了一种新的结膜下注射方法,该方法每隔 3 个月注射一次。对接受新程序的情况、社会情境因素、疾病因素和治疗因素进行评估。
共有 151 名患者参与了这项研究。在这 151 名患者中,有 112 名(74.2%)愿意通过新的结膜下注射方法给予他们的青光眼药物,112 名中的 101 名(90.2%)愿意以与目前药物相同的费用接受新方法,而 101 名中的 87 名(86.1%)愿意即使费用更高也接受这种方法。这些患者往往使用更多的药物(P=0.006),每天需要更频繁地用药(P=0.003)。在被认为不遵医嘱的 10 名患者中,有 9 名(90%)愿意接受每 3 个月一次的结膜下注射,以代替他们的局部用药。
我们的研究发现,74%的青光眼患者愿意接受 3 个月一次的结膜下注射作为替代青光眼治疗方法。很大一部分被认为不遵医嘱使用局部药物的患者愿意考虑这种替代药物治疗方法。我们的发现有助于开发患者可接受的药物输送方案,这可能减轻对每日用药的需求。